Jade Biosciences (JBIO) Cash from Investing Activities (2021 - 2026)

Jade Biosciences' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$8.5 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 165.91% year-over-year to -$8.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$268.3 million (down 1132.86% YoY) and the FY2025 annual result came in at -$247.0 million, down 540.85% from the prior year.
• Cash from Investing Activities was -$8.5 million for Q1 2026 at Jade Biosciences, up from -$98.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $15.4 million in Q1 2023 and bottomed at -$148.7 million in Q3 2025.
• A 5-year average of -$14.3 million and a median of $4.6 million in 2022 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 8394.64% in 2022, while the deepest fall reached 50897.5% in 2022.
• Jade Biosciences' Cash from Investing Activities stood at $14.5 million in 2022, then plunged by 61.01% to $5.6 million in 2023, then jumped by 132.45% to $13.1 million in 2024, then slumped by 847.67% to -$98.2 million in 2025, then soared by 91.37% to -$8.5 million in 2026.
• Business Quant data shows JBIO's Cash from Investing Activities at -$8.5 million in Q1 2026, -$98.2 million in Q4 2025, and -$148.7 million in Q3 2025.